国家医保局，重拳出击！

Core Viewpoint - The article discusses a commercial bribery case involving Shanghai Haiyilai Consulting Management Partnership and its impact on Changshan Pharmaceutical, highlighting the implications for the pharmaceutical industry and regulatory measures taken by the National Medical Insurance Administration [2][6]. Group 1: Case Details - Shanghai Haiyilai was involved in a commercial bribery case while promoting the drug "Dahai Sodium Injection" (Wanmianing) for Shanghai Hongjian Pharmaceutical Co., Ltd. [4] - The sales promotion director of Shanghai Haiyilai promised a kickback to a doctor for prescribing the drug, totaling 35,046 yuan for 18,275 prescriptions during 2023 [5][6]. - The total revenue from the marketing and information services for Wanmianing was 868,677 yuan for the same period [5]. Group 2: Regulatory Actions - The Shanghai market supervision authority fined Shanghai Haiyilai 300,000 yuan for violating the Anti-Unfair Competition Law, emphasizing the negative impact of commercial bribery on fair competition and healthcare costs [6]. - The National Medical Insurance Administration has implemented a credit evaluation system since 2020 to penalize companies involved in bribery and unfair practices, aiming to ensure fair competition in the pharmaceutical market [6][7]. Group 3: Company Impact - Changshan Pharmaceutical, the producer of Wanmianing, is facing scrutiny as the case has led to a credit evaluation process that may affect its operations [7][8]. - The company reported a significant decline in sales for its low molecular weight heparin products, with a 19.17% decrease in overall sales volume and a 27.55% drop in revenue from Dahai Sodium Injection in the first half of 2025 [10]. - As of January 12, 2025, Changshan Pharmaceutical's stock price was 57.79 yuan per share, reflecting a 2.02% decline, with a total market capitalization of 531.13 billion yuan [11].